April 17, 2025
Today, precision medicine provides a biological approach to treatment that considers a patient's genomic information, as well as environmental, lifestyle and social factors. Advancements in genomic testing are fundamentally changing care for cancer and other conditions. These exciting developments, under the umbrella of precision healthcare, are leading to more personalized healthcare delivery that offers competitive advantages to hospitals and health systems embracing this approach. These were key themes of an executive session sponsored by Labcorp at Becker's 12th Annual CEO + CFO Roundtable. In this discussion, three Labcorp leaders- Mahul B. Amin, MD, vice president and divisional medical director; Ken Cerney, vice president of commercial operations; and Ed Esplin, MD, PhD, clinical geneticist and medical director- focused on the role of lab data and genetic testing in the journey to precision medicine and personalized healthcare delivery.In August 2024, Invitae became part of Labcorp to further the future of genetic testing. With Invitae, Labcorp extends its leadership in specialty testing with the most comprehensive offerings in areas such as oncology and select rare diseases and advances its mission to improve health and improve lives.
